Shahab Asgharzadeh

Shahab Asgharzadeh is a Professor of Pediatrics and Pathology at the Keck School of Medicine, University of Southern California. His research focuses on pediatric oncology, particularly neuroblastoma, with emphasis on tumor microenvironment interactions, immunotherapy strategies, and molecular mechanisms of cancer progression. He leads studies on CAR-T cell therapies, chemoresistance mechanisms, and biomarker discovery for high-risk neuroblastoma patients.

His work integrates stem cell biology, epigenetics, and genomic analysis to uncover therapeutic targets. Notable contributions include identifying AF1q as a neuroblastoma biomarker and elucidating ALK-driven tumor pathways. He collaborates with the Children’s Oncology Group (COG) on clinical trials evaluating novel therapeutics and risk stratification systems.

Key research trends in his articles include: 1) Development of targeted immunotherapies to enhance specificity and reduce toxicity, 2) Molecular characterization of tumor heterogeneity and drug resistance, 3) Role of cytokine signaling (e.g., CCL2, TGF-β) in tumor progression and immune evasion. His studies frequently involve mouse models, patient-derived xenografts, and genomic profiling to bridge basic science and clinical applications.

His clinical contributions include optimizing vitamin D regimens in stem cell transplantation and refining risk classification systems for neuroblastoma. He holds no explicitly stated awards but has authored over 300 peer-reviewed publications since 2004.